Ibrolipim
Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL) -promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects[1][2][3].
Product Specifications
CAS Number
133208-93-2
Product Name Alternative
NO-1886
UNSPSC
12352005
Hazard Statement
H301
Target
Lipase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ibrolipim.html
Purity
99.48
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
BrC1=CC(C#N)=C(C=C1)NC(C2=CC=C(C=C2)CP(OCC)(OCC)=O)=O
Molecular Formula
C19H20BrN2O4P
Molecular Weight
451.25
Precautions
H301
References & Citations
[1]Chen SG, et al. Ibrolipim increases ABCA1/G1 expression by the LXRα signaling pathway in THP-1 macrophage-derived foam cells. Acta Pharmacol Sin. 2010 Oct;31 (10) :1343-9.|[2]Kano S, et al. NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats. Metabolism. 2006 Feb;55 (2) :151-8.|[3]Liu Y, et al. Preventive effect of Ibrolipim on suppressing lipid accumulation and increasing lipoprotein lipase in the kidneys of diet-induced diabetic minipigs. Lipids Health Dis. 2011 Jul 16;10:117.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
